| Ticker | FHTX |
|---|---|
| ISIN | US3441741077 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory ...
Foghorn Therapeutics Inc. opera en el sector Healthcare, industria Biotechnology.